FGFR3 and neoplasm: Our data also demonstrate that the effects of BGJ-398 are largely cytostatic (rather than cytotoxic), so clinical “responses” may not be associated with tumor regression, and in future studies we plan to investigate whether FGFR3 inhibition can promote the cytotoxic effects of conventional chemotherapy and/or other investigational agents.